Novo’s Amylin Injectable Cagrilintide Hits 11.8% Weight Reduction in Phase III Trial

The sub-analysis, presented at the European Association for the Study of Diabetes congress, showed improved safety data to counteract past tolerability issues.

Scroll to Top